[1] LOU Jingjing, LI Tongtong, LIU Xingdang et al. Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration-resistant prostate cancer and bone metastases[J]. Nuclear Techniques, 44, 120301(2021).

[2] Benabdallah N, Bernardini M, Bianciardi M et al. 223Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification[J]. EJNMMI Research, 9, 20(2019).

[3] Gustafsson J, Rodeño E, Mínguez P. Feasibility and limitations of quantitative SPECT for 223Ra[J]. Physics in Medicine and Biology, 65, 085012(2020).

[4] Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. New England Journal of Medicine, 369, 213-223(2013).

[5] Abou D S, Pickett J, Mattson J E et al. A radium-223 microgenerator from cyclotron-produced trace actinium-227[J]. Applied Radiation and Isotopes, 119, 36-42(2017).

[6] Adler S, Baidoo K, Jagoda E et al. A study of 219Rn outgassing and 211Pb contamination from 223Ra in dry, liquid, and murine tissue samples[J]. Health Physics, 118, 149-161(2020).

[7] Jiang W, Ulmert D, Simons B W et al. The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates[J]. Nuclear Medicine and Biology, 62, 1-8(2018).

[8] Subbiah V, Anderson P, Rohren E. Alpha emitter radium 223 in high-risk osteosarcoma: first clinical evidence of response and blood-brain barrier penetration[J]. JAMA Oncology, 1, 253-255(2015).

[9] Kairemo K, Rohren E M, Anderson P M et al. Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST[J]. ESMO Open, 4, e000439(2019).

[10] WU Han, JU Zizhao, ZHANG Jinming et al. Study on quality control model of PET/CT quality control and evaluation system in China[J]. Chinese Computed Medical Imaging, 27, 42-46(2021).

[11] Gafita A, Rauscher I, Fendler W P et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria[J]. European Journal of Nuclear Medicine and Molecular Imaging, 49, 4271-4281(2022).

[12] Benabdallah N, Scheve W, Dunn N et al. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes[J]. Theranostics, 11, 9721-9737(2021).

[13] Henriksen G, Fisher D R, Roeske J C et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice[J]. Journal of Nuclear Medicine, 44, 252-259(2003).

[14] Carrasquillo J A, O'Donoghue J A, Pandit-Taskar N et al. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer[J]. European Journal of Nuclear Medicine and Molecular Imaging, 40, 1384-1393(2013).

[15] Larsson E, Brolin G, Cleton A et al. Feasibility of thorium-227/radium-223 gamma-camera imaging during radionuclide therapy[J]. Cancer Biotherapy & Radiopharmaceuticals, 35, 540-548(2020).

[16] Owaki Y, Nakahara T, Kosaka T et al. Ra-223 SPECT for semi-quantitative analysis in comparison with Tc-99m HMDP SPECT: phantom study and initial clinical experience[J]. EJNMMI Research, 7, 81(2017).

[17] St James S, Bednarz B, Benedict S et al. Current status of radiopharmaceutical therapy[J]. International Journal of Radiation Oncology, Biology, Physics, 109, 891-901(2021).

[18] Pacilio M, Cassano B, Chiesa C et al. The Italian multicentre dosimetric study for lesion dosimetry in 223Ra therapy of bone metastases: calibration protocol of gamma cameras and patient eligibility criteria[J]. Physica Medica, 32, 1731-1737(2016).

[19] Jonasdottir T J, Fisher D R, Borrebaek J et al. First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent[J]. Anticancer Research, 26, 2841-2848(2006).

[20] Abou D S, Rittenbach A, Tomlinson R E et al. Preclinical single photon emission computed tomography of alpha particle-emitting radium-223[J]. Cancer Biotherapy & Radiopharmaceuticals, 35, 520-529(2020).

[21] Murray I, Chittenden S J, Denis-Bacelar A M et al. The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer[J]. European Journal of Nuclear Medicine and Molecular Imaging, 44, 1832-1844(2017).